Scholarlink

Introduction <p>This qualitative study was conducted to assess participants’ understanding of the PrEPVacc trial design and factors that influenced decisions to participate in the trial. PrEPVacc was a phase IIb, three-arm, two-stage HIV prophylactic vaccine trial with a second randomisation to oral pre-exposure prophylaxis. The main objective was to assess the safety and efficacy of two HIV-1 prophylactic vaccine regimens, each compared to placebo, in preventing the acquisition of HIV.</p> Methods <p>Using a longitudinal approach, qualitative data were collected between October 2021 and September 2023. A sample of 105 participants (7% of trial participants) was purposively selected to participate in three in-depth interviews at 2, 6, and 12&#xa0;months during the trial. Another 111 (92 females and 19 males) participated in 14 focus group discussions across four sites. Data were analyzed thematically.</p> Results <p>Repeated information sharing sessions facilitated by health workers helped participants understand key trial concepts and the design. Pre-exposure prophylaxis (PrEP) was widely recognised as a protective measure alongside experimental vaccines. While vaccines were preferred for convenience and minimal side effects, individual perceived HIV risk was a main motivation for adhering to PrEP. Supportive relationships with health workers and close family members encouraged engagement in the trial, including acceptance to use the products. However, misinformation and stigma in communities created barriers to participation, with some participants facing social harm.</p> Conclusion <p>Overall, participants demonstrated a good understanding of randomisation, double-blinding, and placebo control, facilitated by clear, repeated communication from health workers. Strengthening strategies to enhance informed consent, reduce stigma, and promote trial acceptance is crucial for successful implementation and retention.</p> Clinical trial registration <p>ClinicalTrials.gov NCT04066881. Registered on&#xa0;December 15, 2020.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Understanding trial designs and acceptability of participation in an HIV vaccine trial with concurrent randomisation to oral pre-exposure prophylaxis in East and Southern Africa: a longitudinal qualitative study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月16日

查看全文
  • Rachel Kawuma,
  • Sarah Nakamanya,
  • Edith Tarimo,
  • Rujeko Samanthia Chimukuche,
  • Jane Ambindwile,
  • Doreen Pamba,
  • Sylvia Kusemererwa,
  • Patricia Munseri,
  • Nishanta Singh,
  • Karine Dubé,
  • Sheena McCormack,
  • Eugene Ruzagira,
  • Janet Seeley,
  • Glenda Gray,
  • Zakir Gaffoor,
  • Neetha Morar,
  • Thandiwe Sithole,
  • Kubashni Woeber,
  • Samantha Siva,
  • Eldinah Hwengwere,
  • Rujeko Samanthia Chidawanyika,
  • Nteboheleng Mahapa,
  • Phindile Khanyile,
  • Lucas Maganga,
  • Wiston William,
  • Emmanuel Kapesa,
  • Elizabeth Danstan,
  • Marco Missanga,
  • Amani Kway,
  • Abisai Kisinda,
  • Lilian Njovu,
  • Lwitiho Sudi,
  • Revocatus Kunambi,
  • Said Aboud,
  • Eligius Lyamuya,
  • Frank Msafiri,
  • Agricola Joachim,
  • Diana Faini,
  • Tumaini Nagu,
  • Deus Buma,
  • Muhammad Bakari,
  • Pontiano Kaleebu,
  • Freddie Mukasa Kibengo,
  • Ayoub Kakande,
  • Jennifer Serwanga,
  • Christian Hansen,
  • Sheila Kansiime,
  • Sylvia Masawi,
  • Vincent Basajja,
  • Shamim Nabukenya,
  • Gertrude Mutonyi,
  • Ilesh Jani,
  • Edna Viegas,
  • Isabel Remane,
  • Odete Bule,
  • Edna Nhacule,
  • Patricia Ramgi,
  • Raquel Chissumba,
  • Eduardo Namalango,
  • Yolanda Manganhe,
  • Carmelia Massingue,
  • Igor Capitine,
  • Jorge Ribeiro,
  • Jonathan Weber,
  • Cherry Kingsley,
  • Tom Miller,
  • Angela Crook,
  • David Dunn,
  • Henry Bern,
  • Aminata Sy,
  • Simona Salomone,
  • Liz Brodnicki,
  • Sarah Joseph,
  • Claire Wenden,
  • Giuseppe Pantaleo,
  • Song Ding,
  • Charlotta Nilsson,
  • Arne Kroidl,
  • Julie Fox,
  • Gustavo Doncel,
  • Allison Matthews,
  • Jim Rooney,
  • Carter Lee,
  • Merlin Robb,
  • Kundai Chinyenze,
  • Jacqueline Musau,
  • Mabela Matsoso,
  • Mary Amondi,
  • Ansuya Naidoo,
  • Paramesh Chetty,
  • Anne Gumbe,
  • Silindile Zulu,
  • Londiwe Shandu,
  • Tausi Sade,
  • Gift Gadiel,
  • Joel Ambikile Seme,
  • Masunga Iseselo,
  • Georgina Nabaggala,
  • Esther Awino

摘要

Introduction

This qualitative study was conducted to assess participants’ understanding of the PrEPVacc trial design and factors that influenced decisions to participate in the trial. PrEPVacc was a phase IIb, three-arm, two-stage HIV prophylactic vaccine trial with a second randomisation to oral pre-exposure prophylaxis. The main objective was to assess the safety and efficacy of two HIV-1 prophylactic vaccine regimens, each compared to placebo, in preventing the acquisition of HIV.

Methods

Using a longitudinal approach, qualitative data were collected between October 2021 and September 2023. A sample of 105 participants (7% of trial participants) was purposively selected to participate in three in-depth interviews at 2, 6, and 12 months during the trial. Another 111 (92 females and 19 males) participated in 14 focus group discussions across four sites. Data were analyzed thematically.

Results

Repeated information sharing sessions facilitated by health workers helped participants understand key trial concepts and the design. Pre-exposure prophylaxis (PrEP) was widely recognised as a protective measure alongside experimental vaccines. While vaccines were preferred for convenience and minimal side effects, individual perceived HIV risk was a main motivation for adhering to PrEP. Supportive relationships with health workers and close family members encouraged engagement in the trial, including acceptance to use the products. However, misinformation and stigma in communities created barriers to participation, with some participants facing social harm.

Conclusion

Overall, participants demonstrated a good understanding of randomisation, double-blinding, and placebo control, facilitated by clear, repeated communication from health workers. Strengthening strategies to enhance informed consent, reduce stigma, and promote trial acceptance is crucial for successful implementation and retention.

Clinical trial registration

ClinicalTrials.gov NCT04066881. Registered on December 15, 2020.